Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Investigation

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1172/JCI75938PMID 24983321PMCID PMC4109554
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness.

  2014cited by this paper
• Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus.

  2014cited by this paper
• Association of the IFNL 4-Δ G Allele With Impaired Spontaneous Clearance of Hepatitis C Virus

  2014cited by this paper
• IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.

  2014cited by this paper
• Hepatic interferon‐stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin‐28B genotypes

  2014cited by this paper
• Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver

  2014cited by this paper
• IFNL3 (IL28B) favorable genotype escapes hepatitis C virus-induced microRNAs and mRNA decay

  2013cited by this paper
• Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

  2013influential reference
• Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection.

  2013cited by this paper
• Sofosbuvir for previously untreated chronic hepatitis C infection.

  2013cited by this paper
• Immune surveillance by the liver

  2013cited by this paper
• 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end

  2013influential reference
• IFN-γ production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells.

  2013cited by this paper
• Interferon-λ4 (IFNL4) Transcript Expression in Human Liver Tissue Samples

  2013cited by this paper
• Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

  2013cited by this paper
• Current and future therapies for hepatitis C virus infection.

  2013cited by this paper
• Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells

  2013cited by this paper
• Emerging concepts in immunity to hepatitis C virus infection.

  2013cited by this paper
• Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.

  2013cited by this paper
• Regulation of type I interferon responses

  2013cited by this paper
• A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

  2013cited by this paper
• Review of direct-acting antiviral agents for the treatment of chronic hepatitis C

  2013cited by this paper
• Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question?

  2013cited by this paper
• Hepatitis C virus therapy update 2013

  2013cited by this paper
• Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

  2013cited by this paper
• Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection.

  2013cited by this paper
• RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues.

  2012cited by this paper
• Does IL28B genotyping still have a role in the era of direct‐acting antiviral therapy for chronic hepatitis C infection?

  2012cited by this paper
• Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus–mediated liver disease posttransplantation

  2012cited by this paper
• HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.

  2012cited by this paper
• The resolution of inflammation

  2012cited by this paper
• INTERFEROME v2.0: an updated database of annotated interferon-regulated genes

  2012cited by this paper
• Identification of type I and type II interferon‐induced effectors controlling hepatitis C virus replication

  2012cited by this paper
• IFITM1 is a tight junction protein that inhibits hepatitis C virus entry†, ‡

  2012cited by this paper
• Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype.

  2012cited by this paper
• Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.

  2012influential reference
• Genetic variation in IL-28B and spontaneous clearance of hepatitis C virus

  2012cited by this paper
• A variant upstream of IFNL 3 ( IL 28 B ) creating a novel interferon gene IFNL 4 is associated with impaired clearance of hepatitis C virus

  2012cited by this paper
• Mechanisms of fibrosis: therapeutic translation for fibrotic disease

  2012cited by this paper
• Ribavirin Enhances IFN-α Signalling and MxA Expression: A Novel Immune Modulation Mechanism during Treatment of HCV

  2011cited by this paper
• Interferon-lambda and therapy for chronic hepatitis C virus infection.

  2011cited by this paper
• CXCR3 ligands: redundant, collaborative and antagonistic functions

  2011cited by this paper
• Interferon‐β and interferon‐λ signaling is not affected by interferon‐induced refractoriness to interferon‐α in vivo

  2011cited by this paper
• Comparative Analysis of the Lambda-Interferons IL-28A and IL-29 regarding Their Transcriptome and Their Antiviral Properties against Hepatitis C Virus

  2010cited by this paper
• Ribavirin improves early responses to peginterferon through improved interferon signaling.

  2010cited by this paper
• Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

  2009cited by this paper
• Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

  2009cited by this paper
• Interferon signaling and treatment outcome in chronic hepatitis C

  2008cited by this paper
• Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

  2007cited by this paper
• Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.

  2006cited by this paper
• Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics

  2006cited by this paper
• Conclusion

  2006cited by this paper
• Immunol. Cell Biol.

  1995cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• Histological grading and staging of chronic hepatitis.

  1995cited by this paper
• Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

  1981cited by this paper

• Differential Impact of Interferon-Based and Direct-Acting Antiviral Therapies on Bone Metabolism in Chronic Hepatitis C: Insights from Transcriptomic and Clinical Analyses

  2025cites this paper
• Unveiling the nexus between direct-acting antivirals in hepatitis C virus elimination and immune response

  2025cites this paper
• Function of Interferon Lambda Receptor 1 Variants in Stem Cell-Derived Hepatocytes with Abrogated Endogenous IFNLR1

  2025cites this paper
• Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

  2025cites this paper
• Persistence of hepatitis C virus in peripheral blood mononuclear cells of patients who achieved sustained virological response following treatment with direct-acting antivirals is associated with a distinct pre-existing immune exhaustion status

  2025cites this paper
• Assessment of ubiquitin specific Peptidase-18 gene in peripheral blood of chronic hepatitis C patients treated with direct-acting antiviral drugs

  2024cites this paper
• Risk of hepatocellular carcinoma after viral clearance achieved by DAA treatment.

  2024cites this paper
• Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?

  2024cites this paper
• Comprehensive assessment of circulatory miRNAs as potential diagnostic markers in HCV recurrence post liver transplantation.

  2024cites this paper
• Impact of Treatment with Direct Antivirals on Coagulation Parameters in Patients with Hepatitis C Virus-Related Liver Cirrhosis and Sustained Virological Response

  2024cites this paper
• Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients

  2024cites this paper
• Imprinted immune abnormalities in liver transplant patients cured of hepatitis C with antiviral drugs

  2024cites this paper
• Direct acting antivirals eradicate HCV from the liver quickly in people with HIV but do not fully reverse immune activation.

  2024cites this paper
• DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people

  2023cites this paper
• CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy

  2023cites this paper
• Immunological scars after cure of hepatitis C virus infection: Long-HepC?

  2023cites this paper
• Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis

  2023cites this paper
• Hepatitis D infection induces IFN-β-mediated NK cell activation and TRAIL-dependent cytotoxicity

  2023cites this paper
• Serum inducible protein 10 kDa/C‐X‐C motif chemokine 10 levels predict regression of M2BPGi‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents

  2023cites this paper
• Non‐selective dampening of the host immune response after hepatitis C clearance and its association with circulating chemokine and endotoxin levels

  2023cites this paper
• In HIV-Infected Immunological Non-Responders, Hepatitis C Virus Eradication Contributes to Incomplete Normalization of Systemic Inflammation Indexes, but Does Not Lead to Rapid CD4+ T-Cell Count Recovery

  2023cites this paper
• Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong

  2023cites this paper
• Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C

  2022cites this paper
• Prognosis and incidence of immunological and oncological complications after direct-acting antiviral therapy for chronic hepatitis C.

  2022cites this paper
• Soluble immune checkpoint protein CD27 is a novel prognostic biomarker of HCC development in HCV-SVR patients.

  2022cites this paper
• No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.

  2022cites this paper
• Unraveling the Molecular Mechanisms Involved in HCV-Induced Carcinogenesis

  2022influential citation
• Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication

  2022cites this paper
• Downregulation of SOCS1 increases interferon-induced ISGylation during differentiation of induced-pluripotent stem cells to hepatocytes

  2022cites this paper
• The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection

  2022cites this paper
• Monitoring of iron, lipid and liver profiles in Egyptian hepatitis C virus patients on sofosbuvir therapy.

  2022cites this paper
• Deciphering the significance of plasma chemokines as prognostic biomarkers in Pegylated IFN-α-2a /ribavirin-treated chronic hepatitis C genotype 4 patients.

  2022cites this paper
• Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR

  2022cites this paper
• Occult Infection with Hepatitis C Virus: Looking for Clear-Cut Boundaries and Methodological Consensus

  2021influential citation
• Associations between psychosocial factors and circulating cytokines in breast cancer survivors

  2021cites this paper
• Hepatitis C virus treatment with direct‐acting antivirals induces rapid changes in the hepatic proteome

  2021cites this paper
• Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes

  2021cites this paper
• A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection

  2021cites this paper
• Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination

  2021cites this paper
• Hepatitis C Virus Relapse After Ultrashort Direct-Acting Antiviral Therapy Associates With Expression of Genes Involved With Natural Killer-Cell and CD8+ T-Cell Function

  2021cites this paper
• Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals

  2021cites this paper
• Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals

  2021cites this paper
• Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection

  2021cites this paper
• A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis.

  2021cites this paper
• Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure

  2021cites this paper
• Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients

  2021cites this paper
• EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS

  2020cites this paper
• No Association Between DAA Treatment for HCV Infection and Herpes Zoster Infection in Analysis of Data From 37 Clinical Trials.

  2020cites this paper
• Liver immune abnormalities persist after cure of Hepatitis C Virus by anti-viral therapy

  2020cites this paper
• Intrahepatic Viral Kinetics during Direct-Acting Antivirals for Hepatitis C in HIV Co-infection:The ACTG A5335S Substudy.

  2020cites this paper
• The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells

  2020cites this paper
• Impact of direct-acting antivirals on de novo occurrence of hepatocellular carcinoma in hepatitis C virus patients

  2020cites this paper
• Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis

  2020cites this paper
• Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment

  2020cites this paper
• Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy

  2020cites this paper
• Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes

  2020cites this paper
• Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics

  2020cites this paper
• Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response

  2020cites this paper
• Response of Human Liver Tissue to Innate Immune Stimuli

  2020cites this paper
• Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals

  2020influential citation
• Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy

  2020cites this paper
• Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.

  2020cites this paper
• Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment.

  2020cites this paper
• Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection

  2020cites this paper
• Intrahepatic immune changes after hepatitis c virus eradication by direct‐acting antiviral therapy

  2020cites this paper
• Predictor factors of sustained virological response in patients with chronic hepatitis C treated with current direct-acting antiviral drugs

  2020influential citation
• Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

  2020cites this paper
• JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis

  2020cites this paper
• Exploring Secondary Metabolites Database of Apocynaceae, Menispermaceae, and Annonaceae to Select Potential Anti-HCV Compounds.

  2019cites this paper
• Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature

  2019cites this paper
• Neutrocyte-to-lymphocyte ratio predicts the presence of a replicative hepatitis C virus strand after therapy with direct-acting antivirals

  2019cites this paper
• Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents

  2019cites this paper
• Direct-acting antivirals and visceral leishmaniasis: a case report

  2019cites this paper
• Establishment and Characterization of a New Cell Line Permissive for Hepatitis C Virus Infection

  2019cites this paper
• Direct‐acting antivirals and the risk of hepatocellular carcinoma: The end of a polemic?

  2019cites this paper
• Sustained Type I Interferon Reinforces NK Cell–Mediated Cancer Immunosurveillance during Chronic Virus Infection

  2019cites this paper
• Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response

  2019cites this paper
• Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs

  2019cites this paper
• Dynamic changes in innate immune responses during direct‐acting antiviral therapy for HCV infection

  2019cites this paper
• Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

  2019cites this paper
• A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha–Inducible Protein 6

  2019influential citation
• Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct‐acting antiviral drugs

  2019cites this paper
• Follicular T helper cells shape the HCV-specific CD4 T cell repertoire after viral elimination.

  2019cites this paper
• The reduction of miR146b-5p in monocytes and T cells could contribute to the immunopathogenesis of hepatitis C virus infection

  2019cites this paper
• Individual liver plasmacytoid dendritic cells are capable of producing IFNα and multiple additional cytokines during chronic HCV infection

  2019cites this paper
• Induction of Selenoprotein P mRNA during Hepatitis C Virus Infection Inhibits RIG-I-Mediated Antiviral Immunity.

  2019cites this paper
• Dual herpes virus reactivation complicated with encephalitis caused by direct-acting antiviral agents

  2019cites this paper
• Regulation of interferon signaling and HCV-RNA replication by extracellular matrix

  2018cites this paper
• IFN‐free therapy is associated with restoration of type I IFN response in HIV‐1 patients with acute HCV infection who achieve SVR

  2018cites this paper
• Hepatitis B Reactivation With Hepatitis C Treatment: Bringing Some Clarity to the Black Box.

  2018cites this paper
• Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling

  2018cites this paper
• Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals

  2018cites this paper
• HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection

  2018cites this paper
• [Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis].

  2018cites this paper
• Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy

  2018cites this paper
• Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study

  2018cites this paper
• Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response

  2018cites this paper
• Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin

  2018cites this paper
• Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group

  2018cites this paper
• Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection

  2018cites this paper